bearish
Pre-IPO Wuhan YZY Biopharma - Both R&D and Commercialization Capabilities Have yet to Be Proven
685 Views04 Jul 2023 08:55
YZY is serious about drug R&D but its development progress is slow. There're many unanswered questions in the whole direction of BsAb. Either internally or externally, YZY has a long way to go.
Boomeranged on Tue, 5 Sep 2023 08:39
YZY passed the hearing of HKEX. We've analyzed its business, pipeline and concerns in this insight. It should be pointed out that investors have become very rational now, looking for companies with high certainty of commercialization performance and good cashflow - YZY is not qualified. Future valuation performance could hardly be satisfactory. Its valuation should be lower than Alphamab Oncology.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Aug.18) - TCM Formula Granules VBP, Global Financing Rebound, CR Sanjiu20 Aug 2023
- Pre-IPO Mirxes Holding Company - The Profit Model in the Post Pandemic Era Needs to Be Verified17 Aug 2023
- Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks11 Jul 2023
- Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises21 Jun 2023
- China Biotech – The Commercialization Performance and The Outlook18 Apr 2023
- Akeso Biopharma (9926.HK) - Behind the Deal with Summit: A Snake Swallows an Elephant?13 Dec 2022
x